Färre barn behandlas med SSRI, fler begår självmord: Oroväckande trend bland barn och unga i USA

Lakartidningen

Volumn 104, Issue 43, 2007, Pages 3180-3181

  Isacsson, Göran ^a   Bejerot, Susanne ^b   Jarbin, Håkan ^b  

^a STOCKHOLM COUNTY COUNCIL   (Sweden)

^b Norra Stockholms Psykiatri ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; CHILD; HUMAN; RISK FACTOR; SHORT SURVEY; STATISTICS; SUICIDE; SUICIDE ATTEMPT; UNITED STATES;

ADOLESCENT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHILD; FLUOXETINE; HUMANS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SUICIDE; SUICIDE, ATTEMPTED; UNITED STATES;

EID: 35848932722     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (5)

1. European Medicines Agency. Press release. CHMP meeting on paroxetine and other SSRIs. 9 dec 2004. http://www.emea.europa.eu/pdfs/human/press/pr/ 19257004en.pdf
2. US Food and Drug Administration. FDA issues public health advisory on cautions for use of antidepressants in adults and children [FDA talk paper]. 22 mars 2004. http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01283.html
3. Isacsson G, Bejerot S. Har Läkemedelsverket lämnat den evidensbaserade medicinen? Bannlysningen av SSRI till barn och ungdomar vilar på lösan grund. Läkartidningen. 2005;102(6):408-9.
4. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807-20.
5. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164(9):1356-63.